Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Reply to B. Mutlu Sütcüoğlu et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Analysis of the <i>P. lividus</i> sea urchin genome highlights contrasting trends of genomic and regulatory evolution in deuterostomes.

Cell genomics·2023
Same author

Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical Conization.

Vaccines·2023
Same author

Corrigendum to "Assessing the role of minimally invasive radical hysterectomy for early-stage cervical cancer" [Eur. J. Obstet. Gynecol. 275 (2022) 64-69].

European journal of obstetrics, gynecology, and reproductive biology·2022

Related Experiment Video

Updated: May 14, 2026

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

A new rapid methodological strategy to assess BRCA mutational status.

Emilia Vuttariello1, Marco Borra, Celeste Calise

  • 1Functional Genomic Unit, National Cancer Institute, Fondazione "G.Pascale", Via Mariano Semmola, 80131 Naples, Italy.

Molecular Biotechnology
|January 29, 2013
PubMed
Summary

A new PCR-based assay efficiently detects BRCA1 and BRCA2 gene mutations, crucial for diagnosing hereditary breast and ovarian cancer (HBOC). This cost-effective method aids personalized therapy for high-risk women.

More Related Videos

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Related Experiment Videos

Last Updated: May 14, 2026

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Hereditary cancers, particularly breast and ovarian cancers, are often linked to mutations in BRCA1 and BRCA2 genes.
  • Accurate assessment of BRCA mutational status is vital for managing women predisposed to hereditary breast and ovarian cancer (HBOC).
  • Current BRCA screening methods face challenges in cost and turnaround time, creating a bottleneck in clinical management.

Purpose of the Study:

  • To develop a time- and cost-effective PCR-based assay for detecting BRCA1 and BRCA2 mutations.
  • To validate the assay for clinical application in identifying patients with hereditary breast and ovarian cancer (HBOC).

Main Methods:

  • A novel PCR assay was designed using 73 primer pairs covering the entire coding regions of BRCA1 and BRCA2.
  • Primers incorporated universal M13 sequences for standardized direct sequencing post-PCR.
  • The assay was validated on 10 known genomic DNA samples from HBOC patients.

Main Results:

  • Successful PCR amplification and sequencing were achieved for all targeted BRCA1 and BRCA2 amplicons.
  • The assay demonstrated efficacy in detecting mutations in known HBOC patient samples.
  • The developed method proved to be a promising tool for efficient mutation detection.

Conclusions:

  • The developed PCR-based assay offers a time- and cost-effective solution for BRCA mutation detection.
  • This assay is suitable for clinical settings, facilitating timely diagnosis and personalized therapy for HBOC patients.
  • Standardized sequencing conditions using M13 primers enhance the reliability and efficiency of the assay.